PROFESSIONAL EDITION

The largest community of pharma leaders

Clinical Trials

BiomX Announces Dosing of First Subject in Phase 2 Study of BX001 for Acne-Prone Skin

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today...

Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent...

Ocular Therapeutix™ Announces First Patient Dosed in Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of the Signs and Symptoms of Dry...

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions...

BioAge Initiates Phase 2a Trial of BGE-117 in Elderly Patients with Unexplained Anemia

RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target aging to treat severe diseases, today announced that it has commenced...

Recent Articles